Drug profile · INN
salmeterol xinafoate
AIREXAR SPIROMAX
salmeterol xinafoate (AIREXAR SPIROMAX) is a beta-2 adrenergic receptor agonist. Associated with Teva Pharma GmbH. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — salmeterol xinafoate
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- INHALATION
- Patents
- 2
- Programs
- 1
- Data quality
- 0.89
Quick answer
salmeterol xinafoate (AIREXAR SPIROMAX) is a beta-2 adrenergic receptor agonist. Associated with Teva Pharma GmbH. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-2 adrenergic receptor agonist
Primary target: Beta-2 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is salmeterol xinafoate?
salmeterol xinafoate (AIREXAR SPIROMAX) is a beta-2 adrenergic receptor agonist. Associated with Teva Pharma GmbH. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for salmeterol xinafoate?
AIREXAR SPIROMAX is a marketed brand name for salmeterol xinafoate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of salmeterol xinafoate?
salmeterol xinafoate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.